Pharming Group (NASDAQ:PHAR) Sets New 1-Year High – Time to Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $21.34 and last traded at $21.18, with a volume of 29187 shares changing hands. The stock had previously closed at $20.40.

Analysts Set New Price Targets

PHAR has been the subject of several analyst reports. Zacks Research downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Pharming Group Price Performance

The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $1.49 billion and a price-to-earnings ratio of -2,115.88. The company has a 50 day moving average price of $17.55 and a 200 day moving average price of $14.91.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%.The firm had revenue of $97.30 million during the quarter, compared to analyst estimates of $98.22 million. As a group, equities research analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,979 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.